Letermovir Prophalaxis for CMV in Haplo HSCT - Early Experience from Single Center Fron North India (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #795; 602; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); "Second patient had cytopenias and was given pre emptive therapy with Valganciclovir. Letermovir is a highly effective drug in preventing CMV reactivation in high risk transplants especially Haploidentical stem cell transplants. Efficacy of Letermovir in preventing CMV reactivation Side effects of Letermovir Outcome of patients with CMV prophylaxis post Haplo HSCT"
Clinical • Bone Marrow Transplantation • Hematological Disorders • Infectious Disease • Septic Shock
|
|
Divya Doval, MD 1; Dharma Choudhary, DM 1; Jimy Patel, MD 2
|